[High early mortality in a palliative care unit among patients with tracheostomy discharged from an intensive care units].


1. René-Reinert R. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother. 2004;53:918–27. 2. Perrot X, Bernard N, Vial C, Antoine JC, Laurent H, Vial T, et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology. 2006;67:2256–8. 3. Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf. 2007;30:697–703. 4. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Nota informativa 2007/04. Restricciones de uso y advertencias sobre Telitromicina.[citado 18 May 2009]. Disponible en: URL: http://www.agemed.es/actividad/ alertas/usoHumano/seguridad/home.htm. 5. Gleason PP, Walters C, Heaton AH, Schafer JA. Telithromycin: The perils of hasty adoption and persistence of off-label prescribing. J Manag Care Pharm. 2007;13:420–5. 6. Wilkinson JJ, Force RW, Cady PS. Impact of safety warnings on drug utilization: Marketplace life span of cisapride and troglitazone. Pharmacotherapy. 2004; 24:978–86. 7. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: A population-based time-series analysis. CMAJ. 2008;179:438–46.


0 Figures and Tables

    Download Full PDF Version (Non-Commercial Use)